{
  "id": "5c663c547c78d69471000014",
  "type": "summary",
  "question": "What is the mechanism of action of anlotinib?",
  "ideal_answer": "Anlotinib is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGF\u03b2), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). It is used for treatment of cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29454091",
    "http://www.ncbi.nlm.nih.gov/pubmed/30098152",
    "http://www.ncbi.nlm.nih.gov/pubmed/29943374",
    "http://www.ncbi.nlm.nih.gov/pubmed/29438373",
    "http://www.ncbi.nlm.nih.gov/pubmed/30139768",
    "http://www.ncbi.nlm.nih.gov/pubmed/30032842",
    "http://www.ncbi.nlm.nih.gov/pubmed/27716285",
    "http://www.ncbi.nlm.nih.gov/pubmed/29620050",
    "http://www.ncbi.nlm.nih.gov/pubmed/28953502",
    "http://www.ncbi.nlm.nih.gov/pubmed/29764596",
    "http://www.ncbi.nlm.nih.gov/pubmed/29446853",
    "http://www.ncbi.nlm.nih.gov/pubmed/30231931",
    "http://www.ncbi.nlm.nih.gov/pubmed/30146257"
  ],
  "snippets": [
    {
      "text": "Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30139768",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGF\u03b2), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28953502",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the present study, we detailed the pharmacological properties of anlotinib, a highly potent and selective VEGFR2 inhibitor, in preclinical models. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29446853",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this research, we demonstrated that anlotinib, a potent multi-tyrosine kinases inhibitor (TKI), showed a significant inhibitory effect on VEGF/PDGF-BB/FGF-2-induced angiogenesis in vitro and in vivo. Wound healing assay, chamber directional migration assay and tube formation assay indicated that anlotinib inhibited VEGF/PDGF-BB/FGF-2-induced cell migration and formation of capillary-like tubes in endothelial cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454091",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mechanistically, anlotinib inhibits the activation of VEGFR2, PDGFR\u03b2 and FGFR1 as well their common downstream ERK signaling. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454091",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454091",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29438373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29764596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The tolerability profile of anlotinib is similar to that of other tyrosine kinase inhibitors that target VEGFR and other tyrosine kinase-mediated pathways; however, anlotinib has a significantly lower incidence of grade 3 or higher side effects compared to that of sunitinib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30231931",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance\nAnlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30098152",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES\nAnlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD \u03b1/\u03b2, c-Kit and Ret.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30032842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nAnlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR \u03b1/\u03b2, c-Kit, and Ret.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30231931",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30231931",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nAnlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29438373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Collectively, these results indicate that anlotinib is a well-tolerated, orally active VEGFR2 inhibitor that targets angiogenesis in tumor growth, and support ongoing clinical evaluation of anlotinib for a variety of malignancies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29446853",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anlotinib occupied the ATP-binding pocket of VEGFR2 tyrosine kinase and showed high selectivity and inhibitory potency (IC50 <1\u00a0nmol/L) for VEGFR2 relative to other tyrosine kinases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29446853",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although anlotinib, a multi-targeted receptor tyrosine kinase inhibitor has been reported have antitumor effects in many preclinical and clinical trials, little is known about its effect on hepatocellular carcinoma (HCC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30146257",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30098152",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anlotinib is an oral small molecule inhibitor of multiple receptor tyrosine kinases, with a broad spectrum of inhibitory effects on tumour angiogenesis and growth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29943374",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR \u03b1/\u03b2, c-Kit, and Ret.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD \u03b1/\u03b2, c-Kit and Ret.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30032842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29438373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>OBJECTIVES</b>: Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD \u03b1/\u03b2, c-Kit and Ret.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30032842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The tolerability profile of anlotinib is similar to that of other tyrosine kinase inhibitors that target VEGFR and other tyrosine kinase-mediated pathways; however, anlotinib has a significantly lower incidence of grade 3 or higher side effects compared to that of sunitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30231931",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this research, we demonstrated that anlotinib, a potent multi-tyrosine kinases inhibitor (TKI), showed a significant inhibitory effect on VEGF/PDGF-BB/FGF-2-induced angiogenesis in vitro and in vivo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29454091",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD \u03b1/\u03b2, c-Kit and Ret.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30032842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29620050",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": []
}